Public health agency the US Food and Drug Administration stated on Friday that it has approved Mavenclad (cladribine) tablets for treating relapsing forms of multiple sclerosis (MS) in adults, including relapsing-remitting disease and active secondary progressive disease.
MS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communications between the brain and other parts of the body. MS is among the most common causes of neurological disability in young adults and occurs more frequently in women than in men.
This US FDA approval of Mavenclad was granted to EMD Serono Inc.
According to the agency, the use of Mavenclad is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS, due to its safety profile.
In conjunction, the efficacy of Mavenclad was shown in the company's clinical trial in 1,326 patients with relapsing forms of MS who had least one relapse in the previous 12 months. Mavenclad significantly decreased the number of relapses experienced by these patients compared to placebo as well as reduced the progression of disability compared to placebo. Mavenclad must be dispensed with a patient Medication Guide that describes important information about the drug's uses and risks.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference